

AusCann Investor Webinar

12 September 2019 – Leading medical cannabis company **AusCann Group Holdings Limited** (ASX:AC8) (AusCann or ‘the Company’) is pleased to advise that it will host a live audio Investor Webinar on Wednesday 25 September at 09.00 am AWST /11:00 am AEST.

AusCann’s CEO, Mr Ido Kanyon, will provide an overview of the Company’s strategy and latest activities, followed by a Question and Answer (Q&A) session. Questions can be lodged online during the webinar or submitted ahead of time via email at info@auscann.com.au

An audio recording of the webinar will be available on the Auscann website shortly after the session.

To join the event, please register online at URL

<https://attendee.gotowebinar.com/register/6222623786663838731>

ENDS

For more information, please contact:

For Investment Enquiries

Quentin Megson
Chief Operating and Financial Officer
info@auscann.com.au
+61 8 9561 8834

For Media Enquiries

Elodie Castagna
FTI Consulting
elodie.castagna@fticonsulting.com
+61 8 9321 8533

ABOUT AUSCANN

AusCann Group Holdings Limited (ASX:AC8) is an Australian-based Pharmaceutical Company focused on the development, production, and marketing of cannabinoids-based pharmaceuticals within Australia and internationally. AusCann:

- **transforms** the way Medical Cannabis is dispensed today by making Cannabinoids-based Pharmaceutical dose forms accessible to patients, physicians and healthcare providers worldwide.
- **enables** physicians to treat their patients with a reliable, stable, well-characterized pharmaceutical product, monitor treatment results and adjust treatment algorithm using a portfolio of products and formulations.
- **holds** all required Medical Cannabis licenses to operate in Australia following its incorporation in 2014.
- **is targeting** the treatment of chronic pain in Australia initially, whilst exploring global export opportunities and expansion into additional medical areas.